Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
NCT ID: NCT00728351
Last Updated: 2020-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
317 participants
INTERVENTIONAL
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vildagliptin + metformin
vildagliptin + metformin
metformin
metformin
1000 bid metformin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vildagliptin + metformin
metformin
1000 bid metformin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
78 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pine Bluff, Arkansas, United States
Long Beach, California, United States
Denver, Colorado, United States
Bangor, Maine, United States
Billings, Montana, United States
Novartis Investigative Site
New Brunswick, New Jersey, United States
Trenton, New Jersey, United States
Wilmington, North Carolina, United States
Oklahoma City, Oklahoma, United States
Uniontown, Pennsylvania, United States
Taylors, South Carolina, United States
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Norfolk, Virginia, United States
Wenatchee, Washington, United States
Cabinet d'Endocrinologie-Maladies Métaboliques
Annecy, , France
Service Endocrinologic & Metabolisme
Paris, , France
Polycliniques des minguettes
Vénissieux, , France
Hausärztliche Praxis
Aschaffenburg, , Germany
Klinische Forschung Berlin Mitte GmbH
Berlin, , Germany
AVK
Berlin, , Germany
Gemeinschaftspraxis
Celle, , Germany
Malteser KM
Duisburg, , Germany
Untertrintroper Hausarztzentrum
Essen, , Germany
Gefrees, , Germany
Diabeteszentrum Billstedt/Horn
Hamburg, , Germany
Diabetologische Schwerpunktpraxis
Hamburg, , Germany
St. Elisabeth Krankenhaus Leipzig
Leipzig, , Germany
Diabetes-Schwerpunktpraxis Studienambulanz
Leipzig, , Germany
Institut für Diabetes-forschung Münster
Münster, , Germany
Praxis Dr. Alawi
Saarlouis, , Germany
DDT
Siegen, , Germany
Diabetologische Schwerpunktpraxis
Sinsheim, , Germany
Praxis
Wangen, , Germany
Europ-Med Orvosi Szolgaltato Kft
Budaörs, , Hungary
Synexus Magyarorszag
Budapest, , Hungary
Uzsoki Hospital
Budapest, , Hungary
Budapest, , Hungary
Kenezy Hospital
Debrecen, , Hungary
Gyngyosi Korhaz Kft
Gyöngyös, , Hungary
Petz Aladar County
Győr, , Hungary
Selye Janos Korhaz es Rendelointezet
Komárom, , Hungary
DIAPED Kft., MRC
Meggyesalja U., , Hungary
Josa Andras Teaching Hospital
Nyíregyháza, , Hungary
Vas Megyei Markuscvszky Lajos Korhaz
Szombathely, , Hungary
Zala County Hospital
Zalaegerszeg, , Hungary
NZOZ Specjalistyczny Ośrodek Internistyczno - Diabetologiczny Białystok
Bialystok, , Poland
Gdanska Poradnia Cukrzycowa
Gdansk, , Poland
Gabinet Kardiologiczny Mediplus
Gdynia, , Poland
NZOZ "Esculap" S.C.
Gniewkowo, , Poland
SZPZOZ Szpital Zachodni im. Jana Pawla II
Grodzisk Mazowiecki, , Poland
NZOZ Terapia Optima
Katowice, , Poland
Instytut Cantrum Zdrowia Matki Polki
Lodz, , Poland
NZOZ Special-Med
Lublin, , Poland
Szspital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Ponza
Poznan, , Poland
Lecznica Prosen-SMO NZOZ
Warsaw, , Poland
Centrum Leczenia Chorob Cywilizacyjnych
Warsaw, , Poland
NZCZ Regionalna Poradnia Diabetologiczna
Wroclaw, , Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1
Wroclaw, , Poland
Samodzielny Publiczny Szpital Kliniczny NR 1 im. Prof. Stanislawa Szysko SAM
Zabrze, , Poland
Poradnia Diabetologiczna, Zespol Opieki Zdrowotnej w Leczycy
Łęczyca, , Poland
Zespół Opieki Zdrowotnej w Łęczycy, Poradnia Diabetologiczna Łeczyca
Łęczyca, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information on the clinical study
Results for CLMF237A2309 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLMF237A2309
Identifier Type: -
Identifier Source: org_study_id